Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Cell chemical biology(2022)10.1016/j.chembiol.2022.02.002Source: DataRank Database

Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib is a research paper published in Cell chemical biology (2022). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

5 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.47)OA: closedTopics (31)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

W. Lee Kraus ORCID,Sridevi Challa ORCID

Live enrichment

PubMed:35180430 OpenAlex:https://openalex.org/W4212928280

Ovarian Cancer Research Alliance

Grant: GAA202103-0003

National Cancer Institute

Grant: R01 CA229487

National Cancer Institute

Grant: R01 CA251943

Cancer Prevention and Research Institute of Texas

Grant: RP190236

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: R01 DK069710

FWCI

0.47

Citation Percentile

0.6%

Citation Trend

2022

2023

2024

2025

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

BRONZEhttps://doi.org/10.1016/j.chembiol.2022.02.002

publisherhttps://api.elsevier.com/content/article/PII:S2451945622000538?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451945622000538?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35180430

Fields of Study

PARP inhibition in cancer therapyMedicineChemistryAntineoplastic AgentsHumansNeoplasmsPhthalazinesPoly(ADP-ribose) Polymerase Inhibitors

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsHumansNeoplasmsPhthalazines

Keywords

PARP inhibitorNon canonicalPARP1Poly ADP ribose polymeraseCancer researchWee1Dual (grammatical number)ChemistryMedicineBiologyCancerComputational biologyInternal medicineCell biologyGeneticsDNACell cyclePhilosophy

Sustainable Development Goals

SDG 0: Good health and well-being

Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

FAIR Checklist

Authors (2)

Funding (5 grants)

Impact

Open Access

Topics